Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RN
Rein Therapeutics, Inc. Common Stock
RNTX
Mkt Cap
$50.7M
Volume
363.65K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RN
RNTX
RN
Rein Therapeutics, Inc. Common Stock
RNTX
News
·
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Mkt Cap
$50.9M
Volume
363.64K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Rein Therapeutics completed a $57.5 million underwritten public offering of common stock, including full exercise of the over-allotment option. The company will use net proceeds to fully fund its Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis and support operations into Q1 2028. The offering was backed by healthcare-focused investors including Adar1 Capital Management, Ikarian Capital, and Bios Partners.
Benzinga · May 18, 2026
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Rein Therapeutics priced a public offering of 50 million shares at $1.00 per share, raising $50 million in gross proceeds. The company plans to use net proceeds to fully fund its Phase 2 clinical trial of LTI-03 for idiopathic pulmonary fibrosis and for working capital. Based on current operating plans, the company believes the proceeds combined with existing cash will fund operations into 2028.
GlobeNewswire Inc. · May 1, 2026
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight
The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designations, positive clinical trial data, and FDA clinical hold lifts for several promising candidates in 2025-2026.
GlobeNewswire Inc. · Feb 9, 2026
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics received UK regulatory approval to launch a Phase 2 clinical trial for LTI-03, a potential breakthrough treatment for idiopathic pulmonary fibrosis (IPF), targeting fibrosis and lung tissue regeneration.
GlobeNewswire Inc. · Aug 19, 2025
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Rein Therapeutics will present two scientific talks at the IPF Summit 2025, discussing their novel approach to treating idiopathic pulmonary fibrosis (IPF) through innovative molecular research and clinical trial design.
GlobeNewswire Inc. · Aug 14, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
RN
RNTX
Rein Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
RNTX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any RNTX yet.
Related Tickers
Earnings